Please login to the form below

Not currently logged in
Email:
Password:

quarterly sales

This page shows the latest quarterly sales news and features for those working in and with pharma, biotech and healthcare.

Generic threat looms to J&J’s blockbuster Zytiga in US

Generic threat looms to J&J’s blockbuster Zytiga in US

launches. The importance of Zytiga to J&J at the moment can’t really be overstated: its  quarterly sales are nearly $1bn – well over half from the US – and growing at ... Zytiga will enter the market and will result in a significant decline in

Latest news

  • AZ agrees to $320m deal for Zoladex AZ agrees to $320m deal for Zoladex

    products. The deal, which is expected to close by the end of March, will see AZ receive a $250m upfront payment for the rights, with double-digit quarterly sales-based payments ... ongoing. A further $70m is also up for grabs should Zoladex (goserelin

  • GSK's Witty ends on a high, but warns 2017 looking 'uncertain' GSK's Witty ends on a high, but warns 2017 looking 'uncertain'

    Generic competition to big-selling Seretide/Advair in the US could accelerate sales decline. ... Other generics from Mylan and Hikma are under regulatory review, however, which could be directly substitutable and accelerate the decline in the brand's

  • 2017 set to be a 2017 set to be a "defining year" for AZ

    The last AZ drug to fall over the 'patent cliff' - cholesterol-lowerer Crestor (rosuvastatin) - saw sales cut in half in the fourth quarter after the loss of US patent protection, with ... The decline was, however, offset by good growth for non-small

  • Tecentriq growth offsets Avastin's US decline at Roche Tecentriq growth offsets Avastin's US decline at Roche

    Roche is hoping that while Avastin is likely to see some cannibalisation of sales from Tecentriq, combination use could support its older drug. ... Overall, Roche reported a 3% increase in pharma sales to CHF 39bn, and the company is expecting low- to mid

  • AbbVie weak on new drug sales, but Humira stays strong AbbVie weak on new drug sales, but Humira stays strong

    TNF blocker Humira (adalimumab) put in another stellar performance, with sales rising 15.5% to $4.3bn and helping to boost group revenues 6% to $6.8bn. ... Imbruvica - which is also sold by Johnson &Johnson - should hit $2.4bn in sales this year, of

More from news
Approximately 9 fully matching, plus 26 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics